{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:44:57Z","timestamp":1788471897845,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.atherosclerosis.2015.03.004","type":"journal-article","created":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T03:47:32Z","timestamp":1425872852000},"page":"482-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Variability of the LDL-C lowering response to ezetimibe and ezetimibe\u00a0+\u00a0statin therapy in hypercholesterolemic patients"],"prefix":"10.1016","volume":"240","author":[{"given":"Olivier","family":"Descamps","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne E.","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B.","family":"Polis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Brudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib3","first-page":"151","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia\u2013full report","volume":"8","author":"Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel Members","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1-executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib9","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/j.atherosclerosis.2014.05.889","article-title":"Variability of LDL-C response with different doses of simvastatin, atorvastatin and rosuvastatin: results from voyager","volume":"235","author":"Karlson","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib10","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.amjcard.2011.01.050","article-title":"Reaching C-reactive protein and low-density lipoprotein cholesterol goals in dyslipidemic patients (from the Lipid Treatment Assessment Project [L-TAP] 2)","volume":"107","author":"Chiang","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jacl.2010.01.007","article-title":"Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients","volume":"4","author":"Foody","year":"2010","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2010.03.2118","article-title":"LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice","volume":"122","author":"Rublee","year":"2010","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.mol.0000137225.46654.4d","article-title":"Phenotypes, genotypes and response to statin therapy","volume":"15","author":"Caslake","year":"2004","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0002-9149(02)02599-7","article-title":"Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS)","volume":"90","author":"Streja","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.atherosclerosis.2011.06.010","article-title":"Where does the interplay between cholesterol absorption and synthesis in the context of statin and\/or ezetimibe treatment stand today?","volume":"217","author":"Descamps","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.7326\/0003-4819-134-10-200105150-00007","article-title":"Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial","volume":"134","author":"Hunt","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib17","first-page":"555","article-title":"Pharmacogenomics of statin response","volume":"10","author":"Mangravite","year":"2008","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","article-title":"Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study","volume":"97","author":"Simon","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1463-1326.2009.01190.x","article-title":"Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?","volume":"12","author":"Sathyapalan","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib20","doi-asserted-by":"crossref","first-page":"861924","DOI":"10.1155\/2012\/861924","article-title":"Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients","volume":"2012","author":"Karalis","year":"2012","journal-title":"Cholesterol"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2010.03.002","article-title":"Attainment of low-density lipoprotein cholesterol goals in coronary artery disease","volume":"4","author":"Kauffman","year":"2010","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib23","series-title":"Mathematical Statistics with Applications","first-page":"1","author":"Mendenhall","year":"1990"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib24","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib25","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1185\/030079906X132721","article-title":"Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients","volume":"22","author":"Catapano","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1185\/030079908X253663","article-title":"Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia","volume":"24","author":"Assmann","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.numecd.2009.04.014","article-title":"Applicability of non-cholesterol sterols in predicting response in cholesterol metabolism to simvastatin and fluvastatin treatment among hypercholesterolemic men","volume":"20","author":"Nissinen","year":"2010","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1210\/jc.2009-1952","article-title":"Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin","volume":"95","author":"Lakoski","year":"2010","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib29","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.atherosclerosis.2006.10.036","article-title":"Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients","volume":"194","author":"Pisciotta","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/clp.12.88","article-title":"The efficacy and safety of ezetimibe co-administered with statin therapy in various patient groups","volume":"8","author":"Catapano","year":"2013","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib31","unstructured":"Merck & Co. Inc., Vytorin (ezetimibe\/simvastatin) [package insert]. USA. North Wales, PA, Merck\/Schering-Plough Pharmaceuticals, 2012."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib32","series-title":"Zetia (Ezetimibe) [package Insert]. USA","author":"Merck & Co. Inc.","year":"2012"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib33","first-page":"800","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"66","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/clp.10.49","article-title":"Update on the efficacy and safety of combination ezetimibe plus statin therapy","volume":"5","author":"Toth","year":"2010","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib35","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2014.05.020","article-title":"LDL-cholesterol targets after the ACC\/AHA 2013 guidelines: evidence that lower is better?","volume":"64","author":"Ben Yehuda","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib36","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/01.ATV.0000204337.81286.1c","article-title":"Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy","volume":"26","author":"Berge","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1194\/jlr.M001487","article-title":"Baseline cholesterol absorption and the response to ezetimibe\/simvastatin therapy: a post-hoc analysis of the ENHANCE trial","volume":"51","author":"Jakulj","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib38","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.jacc.2014.04.010","article-title":"Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC\/AHA risk assessment guidelines","volume":"63","author":"Amin","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2013.02.027","article-title":"Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg\/dl or >\/= 50% reduction in high-risk patients: results from VOYAGER","volume":"228","author":"Karlson","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nrcardio.2013.216","article-title":"Risk factors: new risk-assessment guidelines-more or less personalized?","volume":"11","author":"Blaha","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib41","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1016\/j.jacc.2014.02.578","article-title":"2013 ACC\/AHA cholesterol treatment guideline: what was done well and what could be done better","volume":"63","author":"Martin","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib42","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.atherosclerosis.2014.05.003","article-title":"Attainment of the anticipated >=50% reduction in LDL-C in the four ACC\/AHA guidelines statin benefit groups: a voyager meta-analysis","volume":"235","author":"Karlson","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib43","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.amjcard.2014.08.032","article-title":"Statins for all?","volume":"114","author":"Grundy","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ahj.2014.05.004","article-title":"Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population","volume":"168","author":"Blazing","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib45","unstructured":"M.A. Blazing, R. Guigliano, C.P. Cannon, et\u00a0al. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial: On-treatment analysis. Presented at the American Heart Association Scientific Sessions 2014; November 15\u201319, 2014; Chicago, IL (Abstract)."},{"key":"10.1016\/j.atherosclerosis.2015.03.004_bib46","unstructured":"C.P. Cannon, On behalf of the IMPROVE-IT investigators. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial. Presented at the American Heart Association Scientific Sessions 2014; November 15\u201319, 2014; Chicago, IL (Abstract)."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501500163X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501500163X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:35:58Z","timestamp":1758155758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191501500163X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S002191501500163X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.03.004","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variability of the LDL-C lowering response to ezetimibe and ezetimibe\u00a0+\u00a0statin therapy in hypercholesterolemic patients","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}